Exelixis, Inc. - Common Stock (NQ:EXEL)

58.61 +0.22 (+0.38%)

Delayed Quote Updated: 12:25 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update

November 01, 2022

From Exelixis, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 ↗

November 01, 2022

Upgrades

Via Benzinga

Exelixis Announces Detailed Results From Late-Stage Cabometyx Combo Trial In Kidney Cancer ↗

September 08, 2022

Via Benzinga

Recap: Exelixis Q2 Earnings ↗

August 09, 2022

Exelixis (NASDAQ:EXEL) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Via Benzinga

Exelixis Handily Beats Second-Quarter Expectations, Retains 2022 Outlook ↗

August 09, 2022

Exelixis stock was flat immediately after the earnings release.

Via Investor's Business Daily

Nasdaq Bear Market: 5 Magnificent Growth Stocks You'll Regret Not Buying on the Dip ↗

October 29, 2022

With the Nasdaq Composite down as much as 38% from its peak, these highly innovative companies are ripe for the picking.

Via The Motley Fool

2 Top Biotech Stocks to Buy for the Long Haul ↗

October 28, 2022

Both drugmakers have outperformed the market in the past year.

Via The Motley Fool

Exelixis Announces Promising Initial Dose-Escalation Results from the First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022

October 26, 2022

From Exelixis, Inc.

Via Business Wire

Worried About Rising Interest Rates? These 2 Growth Stocks Could Offer a Solution ↗

October 19, 2022

These stocks have low-to-no debt, and analysts see tons of upside.

Via The Motley Fool

Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022

October 18, 2022

From Exelixis, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2022 ↗

October 18, 2022

Upgrades

Via Benzinga

The Smartest Stocks to Buy With $20 Right Now ↗

October 14, 2022

Cheap stocks have the ability to generate enormous, long-term profits for investors.

Via The Motley Fool

These 7 Biotech Stocks Are Set to Boom in 2023 ↗

October 10, 2022

This article looks at seven biotech stocks that look like good options to move significantly higher in 2023

Via InvestorPlace

Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 Trial

October 04, 2022

From Exelixis, Inc.

Via Business Wire

3 Biotech Stocks to Buy Now for Extraordinary Gains ↗

September 20, 2022

These biotech stocks should deliver big gains to long-term investors who purchase shares at a discount during the bear market.

Via InvestorPlace

Exelixis' XL092/ Atezolizumab Shows Encouraging Efficacy, Safety In Heavily Pretreated Cancer Patients ↗

September 12, 2022

Via Benzinga

Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022

September 10, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022

September 07, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis To Webcast Fireside Chats as Part of Investor Conferences in September

September 06, 2022

From Exelixis, Inc.

Via Business Wire

Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review ↗

August 12, 2022

The major indexes continued to advance, despite some key warnings.

Via Investor's Business Daily

Exelixis Announces Second Quarter 2022 Financial Results and Provides Corporate Update

August 09, 2022

From Exelixis, Inc.

Via Business Wire

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful ↗

August 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

July 26, 2022

From Exelixis, Inc.

Via Business Wire

7 Undervalued Biotech Stocks to Buy Before They Boom ↗

July 25, 2022

Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy.

Via InvestorPlace

Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer

July 11, 2022

From Exelixis, Inc.

Via Business Wire

7 Best Biotech Stocks to Buy in July 2022 ↗

July 08, 2022

The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict.

Via InvestorPlace

The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill ↗

July 07, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies

July 07, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference

July 05, 2022

From Exelixis, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2022 ↗

June 24, 2022

Upgrades

Via Benzinga

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.